Graduate Student First Author on PNAS Paper

Three people standing in front of a research poster. One person is giving the Hook 'em Horns hand gesture.
June 13, 2023
Kimberly J. Long, a Ph.D. candidate in the Dalby Lab in the Division of Chemical Biology and Medicinal Chemistry, was a first author of a recent research paper published in the Proceedings of the National Academy of Sciences (PNAS).

Moczygemba and Janzen Earn Promotions

Two women smiling while both wear dark clothing.
February 27, 2023
Two of the college's distinguished faculty in the Division of Health Outcomes and Division of Pharmacy Practice were recommended for promotion by President Hartzell due to their outstanding accomplishments in research, outreach and education. Dr. Tish Moczygemba will assume the rank of professor and Dr. Kristin Janzen will become a clinical associate professor.

Faculty Earn State Grants for Cancer Research

A person in a lab.
September 21, 2022
The Cancer Prevention and Research Institute of Texas (CPRIT) has released its grant research funding awards for the upcoming year. All three awarded research projects at The University of Texas at Austin involve College of Pharmacy faculty.

Summer Programs of Innovation and Diversity

LEADER/PEPP Program participants and leaders sitting together at an outdoor table for lunch.
September 6, 2022
This summer, the office of Diversity, Equity, Accessibility, and Inclusion (DEAI), hosted two intensive summer research programs: Project Engage Pharmacy Program (PEPP) Camp and the Leadership Through Engagement For the Advancement of Diverse Educational Research (LEADER) Program.

PharmE3D Labs Earn National and International Accolades

Brick facade of Pharmacy building with affixed text, "The University of Texas at Austin College of Pharmacy"
July 11, 2022
Researchers in UT Pharmacy's Pharmaceutical Engineering and 3D Printing (PharmE3D) Labs have earned a bevy of national and international awards for their work in pharmaceutical drug delivery and 3D printing personalized medicines.

PharmE3D Labs Receive Federal Funding for 3D Printed Contraception

Four people wearing masks and lab coats.
March 14, 2022
Dr. Mo Maniruzzaman's Pharmaceutical Engineering and 3D Printing Labs have received a federal grant from the United States Agency for International Development (USAID) to develop personalized 3D printed non-hormonal intrauterine devices (IUDs). The project’s goal is to increase global access to long-term and effective contraception while minimizing some of its most debilitating side effects.

PharmE3D Labs Receive R01 Grant for Complex Vaccine Technologies

Three people smiling.
September 24, 2021
The College of Pharmacy’s Pharmaceutical Engineering and 3D Printing (PharmE3D) Labs recently earned a three-year $1.5 million National Institutes of Health (NIH) R01 grant to research novel manufacturing technology for complex vaccine formulations for influenza and other emerging infectious diseases.

Dalby Earns CPRIT Grant for Drug Delivery Program

A person wearing a mask in a lab.
September 16, 2021
The Cancer Prevention and Research Institute of Texas (CPRIT) recently awarded grants to six faculty members at UT Austin, including the Division of Chemical Biology and Medicinal Chemistry's Kevin Dalby, Ph.D. for his Targeted Therapeutic Drug Discovery and Development Program.

PharmE3D Labs Earn Multiple Pharmaceutical Science Distinctions

Three men smiling.
September 10, 2021
The college's Pharmaceutical Engineering and 3D Printing (PharmE3D) labs, led by Assistant Professor in Molecular Pharmaceutics and Drug Delivery Mohammed (Mo) Maniruzzaman, Ph.D., has recently earned several national and international awards and scholarships for outstanding research contributions to the field of pharmaceutical science and technology.

Immunologic Resilience: A New Metric to Accurately Gauge COVID-19’s Path

The COVID-19 virus.
September 8, 2021
UT Pharmacy and UT Health Science Center San Antonio Assistant Professor Grace C. Lee, Pharm.D., Ph.D. is the first author of a recently published study that unveiled a novel concept, “immunologic resilience,” to accurately predict which COVID-19 patients will advance to severe disease and which will not.